Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC4005-0001 in Adults with Increased Body Weight and Liver Fat
NCT07214870Phase 1Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Oct 2025
- Primary completion
- May 2027
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in fatty liver disease (FLD) comparing NNC4005-0001 with Placebo (2 arms). Primary endpoint: Number of Treatment-emergent adverse events. Started Oct 2025; status: active, not recruiting.
02
Drugs
NNC4005-0001
03
Conditions
fatty liver disease (FLD)
Beyond the preview
Go deeper on NCT07214870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07214870.